Impact of vaccinating boys and men against HPV in the United States

• Published in: Vaccine 2010-10, Vol.28 (42), p.6858-6867
• Main Authors: Elbasha, Elamin H, Dasbach, Erik J
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Age; Allergy and Immunology; Applied microbiology; Biological and medical sciences; Cervical cancer; Child; Condylomata acuminata; Condylomata Acuminata - epidemiology; Condylomata Acuminata - prevention & control; Cost-Benefit Analysis; Cost-effectiveness analysis; Disease transmission models; Female; Fundamental and applied biological sciences. Psychology; Herd immunity; Human papillomavirus; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; Humans; Intraepithelial neoplasia; Male; Medical sciences; Men; Microbiology; Miscellaneous; Models, Theoretical; Mortality; Papillomavirus Infections - epidemiology; Papillomavirus Infections - prevention & control; Papillomavirus Vaccines - administration & dosage; Papillomavirus Vaccines - economics; Probabilitistic sensitivity analysis; Public Health; Quality-Adjusted Life Years; Recurrent respiratory papillomatoses; Tumors; United States - epidemiology; Uterine cervical neoplasms; Uterine Cervical Neoplasms - epidemiology; Uterine Cervical Neoplasms - prevention & control; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Virology; Vulvar, vaginal, anal, oral cavity, and oropharyngeal cancer; Young Adult
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2010.08.030

Abstract We assessed the public health impact and value of vaccinating boys and men with the quadrivalent HPV vaccine in the United States. We used mathematical population models, accounting for both the direct and indirect protective effects of vaccination. Inputs for the models were obtained from public data sources, published literature, and analyses of clinical trial data. Compared with a program of vaccinating girls and women only, including boys and men 9–26 years of age would further decrease the cumulative mean number of genital wart cases, cervical intraepithelial neoplasia 2/3 cases, cancer cases, and cancer deaths by 5,146,000, 708,000, 116,000, and 40,000, respectively, within 100 years. The mean cost-effectiveness ratio (2008 US $) of this strategy was $25,700 (range: 13,600–48,800) per QALY gained if vaccination protects against all HPV 6/11/16/18-associated diseases, and $69,000 (range: 37,700–152,300)/QALY if it only protects against diseases currently in the vaccine indication. Vaccinating boys and men age 9–26 against all HPV 6/11/16/18-associated diseases provides substantial public health benefits and is cost-effective at commonly cited thresholds.